newsroom
DigiMax Completes Acquisition of DataNavee
Pursuant to the terms of the share purchase and exchange agreement, DigiMax issued the shareholders of DataNavee 55,000,000 common shares of DigiMax in exchange for 100% of the issued and outstanding shares of DataNavee.
Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19
Revive Therapeutics is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders.
Predictiv AI Inc. Announces Successful Results in Performance Testing of ThermalPass Fever Detection System
Predictiv AI Inc. is a technology company which helps businesses and organizations make smarter decisions using advanced artificial intelligence, deep machine learning and data science techniques.
Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder
Revive Therapeutics is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders.